12 Recruiting Studies Using Lhrh Agonist
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Lhrh Agonist
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
📍 Alaska Oncology & Hematology, LLC — Anchorage, Alaska
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
📍 Southern Cancer Center — Daphne, Alabama
Early Breast Cancer
View Study & Checklist ➔Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
Prostate Cancer
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
📍 Arizona Clinical Research Center, Inc — Tucson, Arizona
Locally Advanced or Metastatic Breast Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
📍 Orange Coast Memorial Medical Center — Fountain Valley, California
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
View Study & Checklist ➔Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
📍 University of California San Diego - Moores Cancer Center — La Jolla, California
Prostate Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
📍 Northwest Georgia Oncology Centers PC - Marietta — Marietta, Georgia
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
View Study & Checklist ➔TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
📍 Stamford Hospital — Stamford, Connecticut
Breast Cancer
View Study & Checklist ➔A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
📍 University of Colorado — Aurora, Colorado
Breast Cancer
View Study & Checklist ➔Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
📍 Providence Cancer Center — Anchorage, Alaska
Prostate Cancer
View Study & Checklist ➔Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
📍 The University of Illinois at Chicago (UIC) — Chicago, Illinois
Elderly
View Study & Checklist ➔A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
📍 Southern Cancer Center — Daphne, Alabama
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
View Study & Checklist ➔